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Abstract
Objectives To compare patient acceptability and burden of magnetic resonance enterography (MRE) and ultrasound (US) to each
other, and to other enteric investigations, particularly colonoscopy.
Methods 159 patients (mean age 38, 94 female) with newly diagnosed or relapsing Crohn’s disease, prospectively recruited to a
multicentre diagnostic accuracy study comparing MRE and US completed an experience questionnaire on the burden and
acceptability of small bowel investigations between December 2013 and September 2016. Acceptability, recovery time, scan
burden and willingness to repeat the test were analysed using the Wilcoxon signed rank and McNemar tests; and group
differences in scan burden with Mann–Whitney U and Kruskal–Wallis tests.
Results Overall, 128 (88%) patients rated MRE as very or fairly acceptable, lower than US (144, 99%; p < 0.001), but greater
than colonoscopy (60, 60%; p < 0.001). MRE recovery time was longer than US (p < 0.001), but shorter than colonoscopy (p <
0.001). Patients were less willing to undergo MRE again than US (127 vs. 133, 91% vs. 99%; p = 0.012), but more willing than
for colonoscopy (68, 75%; p = 0.017). MRE generated greater burden than US (p < 0.001), although burden scores were low.
Younger age and emotional distress were associated with greater MRE and US burden. Higher MRE discomfort was associated
with patient preference for US (p = 0.053). Patients rated test accuracy as more important than scan discomfort.
Conclusions MRE and US are well tolerated. AlthoughMRE generates greater burden, longer recovery and is less preferred than
US, it is more acceptable than colonoscopy. Patients, however, place greater emphasis on diagnostic accuracy than burden.
Key Points
• MRE and US are rated as acceptable by most patients and superior to colonoscopy.
•MRE generates significantly greater burden and longer recovery times than US, particularly in younger patients and those with
high levels of emotional distress.
•Most patients prefer the experience of undergoing US thanMRE; however, patients rate test accuracy as more importance than
scan burden.
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Introduction
Cross-sectional imaging plays a crucial role in the diagnosis
and follow-up of Crohn’s disease (CD), and is fundamental
to determine disease extent, activity and complications [1].
Although many techniques are available, emphasis is
placed on MR enterography (MRE) and small bowel ultra-
sound (US) given the potential detrimental effects of re-
peated ionising radiation exposure associated with CT [1,
2]. Meta-analyses suggest that MRE and US are largely
equivalent in terms of accuracy, although most comparative
studies to date have been relatively small and single site
[3–5], and implementation has been governed largely by
availability, local expertise and clinician preference [6, 7].
However the results of the METRIC trial, a large prospec-
tive multicentre diagnostic accuracy study, have shown that
although both MRE and US have high accuracy for the
extent and activity of small bowel Crohn’s disease, MRE
is superior to US when tested in a national health service
setting [8, 9].
Patient experience and acceptability will influence test
utility. While MRE and US avoid radiation, they have their
own specific attributes which may impact on tolerance. For
example, patients must ingest large volumes of oral contrast
for MRE, and US requires abdominal compression.
Patients’ perceptions of test Bburden^ (levels of physical
and psychological discomfort) can impact on compliance,
even if the test is diagnostically superior to alternatives, as
exemplified by low uptake of colorectal cancer screening
colonoscopy [10]. This diminishes test utility. Indeed, pa-
tients may delay seeking medical attention, fearing the dis-
comfort associated with procedures such as colonoscopy
[11]. To date little data reports imaging test preferences
amongst patients with CD, and available data largely com-
pares now largely obsolete investigations such as barium
enema and enteroclysis [1].
The purpose of our study was to compare the perceived
burden and acceptability of MRE to US, and to other enteric
investigations in patients recruited to the METRIC trial [8], to
identify predictors of scan preference and to determine the
perceived importance of different scan attributes.
Materials and methods
Participants
The METRIC trial protocol was published previously [8], and
the main trial was recently reported [9]. In summary, patients
with newly diagnosed CD, or with known CD and suspected
luminal relapse, were prospectively recruited from eight hos-
pitals and underwent MRE and US, in addition to other small
bowel investigations performed as part of usual clinical care.
Patients with newly diagnosed CD had already undergone
colonoscopy or had this pending; patients with suspected re-
lapse only underwent colonoscopy if clinically indicated.
Overall, 335 patients were recruited and all were given the
option to complete a patient experience questionnaire investi-
gating their experience. In total 324 (97%) consented to take
part in the experience substudy, of whom 159 completed the
questionnaire (48% of total recruitment) (see Fig. 1).
Questionnaire distribution
Patients were provided with paper copies of the questionnaire
at the time of consent by a member of their local trial team, or
these were posted if this was not possible. A stamped ad-
dressed envelope for return was provided and patients were
asked to complete the questionnaire only after all their inves-
tigations were completed for that particular diagnostic epi-
sode. Patients were encouraged to contact their clinical team
if they were unsure whether they had completed their current
round of investigations. Participants were asked to record the
date of questionnaire completion.
Questionnaire content
Demographics: Patients were asked their age, gender, educa-
tional level and ethnicity. Missing demographic data on age
and gender were supplied via the central trial database.
Physical and emotional well-being: Emotional distress was
assessed using the General Health Questionnaire GHQ-12
[12]. An example item is, BIn the last three months have
you….been feeling unhappy and depressed^. Using the
GHQ-12 binary coding method (0,0,1,1), a mean sum score
was created ranging from 0 to 12. A score of 4 or higher is
considered indicative of significant distress levels [13].
Co-morbidity was assessed by asking patients about their
current and recent physical health and mental well-being.
Patients were asked to report (Byes^ or Bno^) whether they
had any of the following diseases: heart or vascular disease,
diabetes, epilepsy, stroke, arthritis, asthma, mental or emotion-
al disorder. There was also an option to provide details of other
illness. A response of Byes^ to any illness was coded and
summed to form a dichotomous Bco-morbidity^ variable
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(Bpresent^ or Babsent^), but mental or emotional disorder was
omitted since this was captured by the GHQ-12.
Scan recovery, overall acceptability and willingness
to have again
The questionnaire was divided into sections pertaining to
MRE, US, hydro-US (ultrasound performed following oral
contrast administration), barium follow-through (BaFT),
CTE enterography (CTE) and colonoscopy. Patients were
asked to indicate whether they had undergone the test and, if
so, complete the relevant sections, or otherwise to leave that
section blank.
For each investigation, patients graded their recovery time on
a 9-point scale ranging from Bimmediate^ to Ba week^. Data
were collapsed into six categories for analysis (see BResults^).
Patients rated how acceptable they found investigations on
a 4-point scale: Bnot at all acceptable^ to Bvery acceptable^
(see BResults^). Patients were also asked to select the least
acceptable (or worst) part of the investigation from a range
of attributes provided, specific to the particular investigation.
For example, exposure to ionising radiation was listed as an
option for CTE and BaFT, and laxative requirement listed for
colonoscopy (see Figs. 2, 3 and 4, plus Supplementary Figs.
1–3). Patients were also asked if they would repeat the inves-
tigation if necessary (with response options Byes^, Bno^,
Bnot sure^).
Fig. 1 Flow chart showing flow
of participants in study
Fig. 2 Comparative scan
experience: least acceptable part
of MR enterography
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Scan burden for MRE and US
Scan burden for MRE and US was quantified using a ques-
tionnaire adapted from that used to assess colonoscopy and
whole-bodyMRI [14, 15] (Supplementary Data 1 and 2). Five
additional items of direct relevance to small bowel investiga-
tions were added: abdominal bloating, diarrhoea, nausea,
vomiting and sleep difficulties. The questionnaire combined
a series of individual items into three main domains: satisfac-
tion, worry and discomfort. The MRE questionnaire included
31 items (7, 6 and 18 in satisfaction, worry and discomfort
domains, respectively) and the US questionnaire included 28
items (7, 6 and 15 satisfaction, worry and discomfort domains,
respectively), excluding items pertaining to noise, claustro-
phobia, injections and undesirable side effects, but
additionally including an item relating to the abdominal pres-
sure of the US probe.
Patients rated their experiences using a 1–7 Likert
scale, where 1 and 7 were anchored to bipolar statements
related to the scan, e.g. 1 = Bthe noise of the scanner was
unbearable^ to 7 = Bthe noise of the scanner was fine^.
Scores for each item were reverse scored, totalled and
averaged so that higher scores equated to higher burden.
Internal reliability of subscales was assessed using
Cronbach’s alpha.
Scan preference
Patients were then asked to indicate whether they would prefer
MRE or US if they had to undergo just one test.
Fig. 3 Comparative scan experience: least acceptable part of ultrasound
Fig. 4 Comparative scan experience: least acceptable part of colonoscopy
1086 Eur Radiol (2019) 29:1083–1093
Overall perceived importance of investigation
attributes
Patients were asked to rate how important 25 possible investi-
gation attributes were to them on a 5-point scale: Bnot at all
important^ to Bextremely important^ (Supplementary Data 3).
Higher scores indicated higher levels of perceived importance.
Attributes included diagnostic accuracy and test efficiency to
reach a final diagnosis as well as items specific to certain scans,
for example requirement to drink a large volume of oral contrast.
Statistical analysis
The study was powered to enable comparison of scan bur-
den between MRE and US using theWilcoxon signed rank
test, with a medium effect size (d = 0.5), alpha of 0.05 and
95% power. A minimum number of 57 patients was re-
quired. Analysis was performed using IBM SPSS version
24 (IBM Corp.). Independent t tests and chi-square tests
were used to assess differences between (i) questionnaire
completers and non-completers and (ii) newly diagnosed
and relapse cohorts, for continuous or categorical data re-
spectively. Related samples Wilcoxon sign tests were used
to assess differences between scan recovery time, scan ac-
ceptability and scan burden. McNemar tests were used to
assess willingness to have the different investigations
again. Bonferroni corrections were applied to the latter,
meaning a p < 0.01 threshold for statistical significance.
Differences in perceived MRE and US scan burden be-
tween different subgroups were assessed using Mann–
Whitney U tests or Kruskal–Wallis as appropriate. Post hoc
comparisons using a Bonferroni correction were used to as-
sess the effect of age on scan burden, adopting a p < 0.01
threshold for statistical significance. The time between the
questionnaire completion and the date of MRE and US was
dichotomised into less than 5 weeks or 5 weeks or longer [16]
and any association with scan preference or perceived impor-
tance of different test attributes assessed using chi-square tests
and Spearman’s rho correlation coefficients respectively,
adopting a p < 0.002 threshold following a Bonferroni correc-
tion (0.05/25). We also explored whether a time interval of
less than or more than 1 week influenced scan preference.
Ethical considerations
Ethical approval for the METRIC trial (including the current
study) was obtained from the National Health Service
Research Ethics Committee (NHS REC) in September 2013
(ref: 13/SC/0394).
Results
Participant characteristics are shown in Table 1. Just under
half of participants who consented to complete a questionnaire
actually did so (159/ 324, 49%). Participants completing the
questionnaire were significantly older than non-responders
(mean age, 38.2 vs. 33.8 years; t = 2.603, p = 0.010), but
there were no gender differences between groups (chi-square
= 1.606, p = 0.205) or whether the patient was newly diag-
nosed or relapsing (chi-square = 1.763, p = 0.184).
There were no significant differences in demographics, ed-
ucational level, ethnicity, presence of comorbidities or preva-
lence of significant psychological distress between those with
newly diagnosed CD or suspected relapse. Overall, rates of
Table 1 Participant
characteristics All patients
(N = 159)
New diagnosis
(n = 84)
Relapse
(n = 75)
Group differences
Age 38.2 (16.4) 37.3 (17.3)a 39.1 (15.4)a t < 1, p = 0.484
Female gender 94 (59.1) 47 (56.0)a 47 (62.7)a χ2 = 0.739, p = 0.390
Educational qualifications
None
Some
Degree level or higher
8 (5.1)
91 (58.3)
57 (36.5)
4 (4.9)b
45 (55.6)
32 (39.5)
4 (5.3)a
46 (61.3)
25 (33.3)
χ2 = 0.641 p = 0.726
Ethnicity (white) 127 (92.0) 71 (93.4)c 56 (90.3)c χ2 = 0.447, p = 0.504
Newly diagnosed 84 (52.8)a – – –
Comorbidities
(at least one comorbid illness)
65 (40.9) 35 (41.7)a 30 (40.0)a χ2 = 0.046, p = 0.831
GHQ-12 (presence of high distress) 73 (48.3) 43 (51.2)a 30 (44.8)c χ2 = 0.614, p = 0.433
Data are n (%) unless specified otherwise. Where there is missing data, percentage is valid %
aNo missing data
bMissing data < 5%
cMissing data > 5%
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psychological distress were high, with 48% reporting clinical-
ly significant levels (Table 1).
The median number of days between patients undergoing
the MRE scan and completing the questionnaire was 7 (range
0–326; 46.6 weeks). The median number of days between
patients undergoing the US scan and completing the question-
naire was 6 (range 0–326). The proportion who completed the
questionnaire less than 5 weeks after their MRE and US scan
was 61% (n = 70) and 61% (n = 71) respectively.
The number and percentage of patients who completed the
questions about scan experience across the different imaging
modalities are shown in Supplementary Table 1.
Scan recovery, overall acceptability and willingness
to have again
MRE recovery time was significantly longer than US (z =
9.223, p < 0.001) but shorter than colonoscopy (z = 3.175, p
< 0.001), with 15/146 (10%) reporting immediate recovery
following MRE compared with 102/147 (69%) and 3/98
(3%) for US and colonoscopy respectively (Fig. 5,
Supplementary Table 2). Overall 26/146 (18%) of patients
took more than 1 day to recover from MRE, compared to 3/
147 (2%) for US and 30/98 (31%) for colonoscopy. MRE
recovery was also longer compared with CTE (z = 2.676, p
= 0.007), but not different to BaFT (z = 0.645, p = 0.519). The
difference between MRE and hydro-US approached signifi-
cance (z = 2.245, p = 0.025) (Supplementary Table 2).
Overall, 128/145(88%)ofpatients ratedMREasveryor fairly
acceptable. This was significantly lower than for US 144/146
(99%) (z = 6.696, p < 0.001), but significantly greater than for
colonoscopy60/100 (60%) (z=4.480,p<0.001). Therewereno
differences in acceptability between MRE and hydro-US (z =
0.535, p = 0.593), BaFT (z = 1.567, p = 0.117) and CTE (z =
1.498, p = 0.134) (Table 2). Test acceptability for the new and
relapsing cohorts were consistent with the findings for the
whole cohort overall (Supplementary Tables 3 and 4).
The proportion willing to repeat MRE was high (127/140,
91%), but lower than for US (133/135, 99%) (p = 0.012),
which approached statistical significance at the p < 0.01 thresh-
old. Patients were less willing to repeat colonoscopy (68/91,
75%) versus MRE (p = 0.017) and indeed 9/91 (10%) stated
theywould not be willing to undergo repeat colonoscopy. There
were no significant differences between MRE and hydro-US (p
= 0.219), CTE (p = 1.000), or BaFT (p = 1.000) (Table 2).
Attributes selected as the least acceptable part of MRE, US
and colonoscopy are shown in Figs. 2 to 4 (see Supplementary
Figs. 1–3 for hydro-US, BaFT and CTE). Drinking contrast
(37%) and repeated breath-holding (14%) were most commonly
cited for MRE, followed by Bother^ which comprised mainly
Fig. 5 Recovery time by scan
type (cumulative %)
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side effects of drinking contrast, such as diarrhoea, pain and
wind, feeling sick, abdominal soreness or bloating.
Overall 49% reported US as being Bfine^, with no least
acceptable part, although 30% reported abdominal compres-
sion as the least acceptable aspect. Conversely, for colonosco-
py 55% of patients rated the laxative as the least acceptable
part of the investigation, followed by discomfort (23%).
Scan burden for MRE and US
Internal reliability of the subscales was good: for MRE
the satisfaction subscale Cronbach’s alpha = 0.813, dis-
comfort subscale Cronbach’s alpha = 0.872 and worry
subscale Cronbach’s alpha = 0.786; for US the satisfac-
tion subscale Cronbach’s alpha = 0.849, discomfort sub-
scale Cronbach’s alpha = 0.868 and worry subscale
Cronbach’s alpha = 0.808.
Burden scores for MRE and US are shown in Table 3.
Patients reported higher burden during MRE versus US,
although scores were relatively low overall. There were
significant differences between MRE and US on all three
subscales (discomfort: z = 9.558, p < 0.001; satisfaction: z
= 7.043, p < 0.001; and worry: z = 8.017, p < 0.001).
Differences in MRE scan burden according to patient
demographics and scan preference are shown in Table 4.
Perceived MRE scan burden was significantly higher
among younger people (with significant differences only
between the youngest and oldest age group, z = 2.969, p
= 0.003 following Bonferroni corrections) and people
with high levels of emotional distress. There was a non-
significant trend towards higher MRE scan burden among
patients reporting a preference for US. Younger age and
high levels of emotional distress were also associated with
higher perceived burden of US (see Table 4).
Scan preference
When asked which scan patients would prefer, the ma-
jority who expressed a preference (100/125 [80%]) se-
lected US over MRE. Scan preference was not related
to the time between questionnaire completion and un-
dergoing US (either less than 5 weeks vs. 5 weeks or
longer, or less than 1 vs. 1 week or longer), χ2 = 2.733,
p = 0.098 and χ2 = 0.901, p = 0.343 respectively.
There was also no association between the time of ques-
tionnaire completion and undergoing MRE (less than 5
weeks vs. 5 weeks or longer χ2 = 2.421, p = 0.120, or
less than 1 vs. 1 week or longer χ2 = 2.182, p = 0.140
respectively).
Table 2 Comparative scan acceptability and willingness to have again (all participants)
MR enterography Ultrasound Colonoscopy Hydro-sonography CTE Barium follow-through
Acceptability (n = 145) (n = 146) (n = 100) (n = 46) (n = 31) (n = 24)
Very 66 (45.5) 126 (86.3)b 18 (18.0)b 28 (60.9) 17 (54.8) 8 (33.3)
Fairly 62 (42.8) 18 (12.3) 42 (42.0) 13 (28.3) 12 (38.7) 12 (50.0)
Slightly 12 (8.3) 0 (0) 34 (34.0) 4 (8.7) 2 (6.5) 1 (4.2)
Not at all 5 (3.4) 2 (1.4) 6 (6.0) 1 (2.2) 0 (0) 3 (12.5)
Willingness to have again (n = 140) (n = 135) (n = 91) (n = 42) (n = 28) (n = 22)
Yes 127 (90.7) 133 (98.5)a 68 (74.7)a 40 (95.2) 26 (92.9) 20 (90.9)
Not sure 12 (8.6) 0 (0) 14 (15.4) 2 (4.8) 1 (3.6) 1 (4.5)
No 1 (0.7) 2 (1.5) 9 (9.9) 0 (0) 1 (3.6) 1 (4.5)
Data are n (%). Where there is missing data, percentage is valid %
a Significantly different from MRE p < 0.05
b Significantly different from MRE p < 0.001
Table 3 Perceived scan burden
for MRE and US Scan burden Low (1) to high (7) MR enterography Ultrasound Wilcoxon signed rank test
Overall score 2.72 (0.96) (n = 148) 1.66 (0.74) (n = 149) z = 9.536; p < 0.001
Discomfort subscale
(1–7 = low to high)
3.01 (1.07) (n = 148) 1.65 (0.79) (n = 149) z = 9.558; p < 0.001
Satisfaction subscale
(1–7 = high to low)
2.07 (1.02) (n = 147) 1.49 (0.75) (n = 149) z = 7.043; p < 0.001
Worry subscale
(1–7 = low to high)
2.73 (1.23) (n = 148) 1.88 (1.08) (n = 149) z = 8.017; p < 0.001
Data are means (SDs)
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Overall perceived importance of investigation
attributes
Ratings of test attribute importance (graded from 1 = not at all
important to 5 = extremely important) split according to pa-
tient cohort are shown in Fig. 6. For both cohorts, accuracy
was rated as the most important attribute, followed by waiting
time to diagnosis/ treatment and number of tests needed prior
to final diagnosis. In general, negative physical test attributes
such as requirement to drink fluid, test discomfort and fasting
were rated as less important and generally between Ba little bit
important^ and Bmoderately important^.
There was some evidence that, compared to those complet-
ing questionnaires within 5 weeks of MRE or US, patients
completing questionnaires more than 5 weeks after perceived
several physical attributes as less important (see Supplementary
Table 5). However, none of these associations were significant
following Bonferroni corrections, (p < 0.002).
Discussion
Using questionnaire data from a large number of patients pro-
spectively recruited to a diagnostic accuracy study, we found
that MRE and US are both acceptable and reasonably well
tolerated; most indicated that they would repeat the tests and
scan burden scores were relatively low for both overall.
However, MRE was judged significantly less favourably than
US in terms of recovery time, acceptability, burden (across
satisfaction, worry and discomfort domains) and Bwillingness
to have again^, the last of these approaching significance at
the p < 0.01 threshold. Putting this into context, MREwas still
rated significantly more favourably than colonoscopy, which
was the least acceptable of all tests. As could be anticipated,
the Bworse part^ of the MRE scan was drinking enteric con-
trast beforehand and the associated side effects such as diar-
rhoea and/or abdominal pain/bloating, while conversely al-
most half indicated that US was Ball fine^, with a minority
listing abdominal compression as the worst part.
While our primary focus was MRE and US, we collected
data on other small bowel investigations performed as part of
usual clinical care in recruited patients. Recovery time for
MRE was significantly longer than for CTE. However, we
found no significant difference in recovery time compared to
BaFT. This finding may be secondary to lack of statistical
power contingent on small numbers undergoing BaFT, but it
is possible that the constipating effects of barium contributed
to slower recovery.
Table 4 Group differences in perceived MR enterography and ultrasound scan burden
MR enterography
burden
Group differences Mann–Whitney
U or Kruskal–Wallis test
Ultrasound burden Group differences Mann–Whitney
U or Kruskal–Wallis test
Age χ2 = 11.93, p = 0.008 χ2 = 8.93, p = 0.034
Up to 30 2.95 (0.89) (n = 61) 1.70 (0.60) (n = 61)
30–49 2.72 (0.92)a (n = 52) 1.66 (0.85) (n = 52)
50–64 2.44 (1.12)b (n = 22) 1.83 (0.95) (n = 21)
65 and older 2.08 (0.83)c (n = 13) 1.25 (0.30)c (n = 15)
Gender z = 1.638, p = 0.101 z = 1.268, p = 0.205
Men 2.56 (0.90) (n = 61) 1.57 (0.70) (n = 62)
Women 2.83 (0.98) (n = 87) 1.72 (0.77) (n = 87)
Newly diagnosed or relapsing z = 0.597, p = 0.550 z = 1.099, p = 0.272
Newly diagnosed 2.77 (0.97) (n = 81) 1.69 (0.71) (n = 82
Relapsing 2.65 (0.95) (n = 67) 1.62 (0.78) (n = 67)
Comorbidities z = 0.279, p = 0.780 z = 0.481, p = 0.630
No 2.69 (0.93) (n = 85) 1.64 (0.68) (n = 84)
Yes 2.76 (1.00) (n = 63) 1.68 (0.81) (n = 65)
GHQ-12 z = 2.334, p = 0.020 z = 2.734, p = 0.006
Low distress 2.51 (0.92) (n = 74) 1.53 (0.73) (n = 76)
High distress 2.91 (0.94) (n = 73) 1.80 (0.74) (n = 72)
Scan preference z = 1.934, p = 0.053 z = 0.156, p = 0.876
MRE 2.43 (0.99) (n = 25) 1.82 (1.03) (n = 25)
US 2.81 (0.92) (n = 99) 1.63 (0.69) (n = 99)
a Significantly different from age 65+ at p < 0.05
b Significantly different from age up to 30 at p < 0.05
c Significantly different from age up to 30 at p < 0.01
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In general,MRI is a challenging test for patients. Relatively
long scan times, claustrophobic scanner bore and associated
noise all influence patient experience negatively [17]. Using a
very similar questionnaire to the present study in a sample of
115 patients [15], patient burden during whole-body MRI
(WB-MRI) cancer staging was reported as actually a little
better than we found for MRE (2.21 vs. 2.72) [15].
Interestingly, both studies reported that high levels of emo-
tional distress predicted increased MRI burden, although the
current study found that younger age was also associated.
Indeed, a very large proportion of participants in the current
study reported significant psychological distress, comparable
with high rates of anxiety recently among patients with active
CD [18], and reaching levels more typically reported by pa-
tients being investigated for suspected cancer [19].
It is perhaps unsurprising that most patients stated that they
would choose US over MRE, and indeed MRI scans have
been judged to be more challenging than other scans such as
PET-CT and contrast-enhanced spectral mammography [20,
21]. One very important finding from the current study is that
patients rated several scan attributes as more important than
the challenges and discomfort of undergoing scans. Notably,
diagnostic accuracy was the most important attribute. This is
comparable to data from studies of CT colonography [22].
Patients, at least to some extent, seem tolerant of discomfort
if they believe that the test is more accurate than a less arduous
alternative. We did not provide differential accuracy data for
the tests under investigation, and it is likely that patients as-
sumed they are similar when selecting preferences. The
METRIC study has recently reported [9] and shows that when
compared prospectively, MRE has significantly higher sensi-
tivity for extent (presence and location) of small bowel
Crohn’s disease than US (80% vs. 70%). When viewed in this
context, and given their emphasis on diagnostic accuracy, it
seems that MRE is an acceptable first-line test for patients;
although patients’ experience duringMRE was inferior to US,
absolute levels of scan burden were relatively low and accept-
ability ratings reasonable. The performance of US in the
Fig. 6 Perceived importance of
different scan attributes (mean
scores on a scale of 1–5)
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METRIC trial was, however, still good, particularly for small
bowel disease presence, and the technique still undoubtedly
has a major role in managing Crohn’s disease patients. It is
clearly a very well tolerated test by patients and completely
safe, an important attribute given the potential deleterious ef-
fect of gadolinium deposition with repeated MRE [23–25].
Perhaps surprisingly, patients did not rate radiation exposure
as particularly important, although again this may be influ-
enced by their knowledge of this issue.
A very important consideration in questionnaire stud-
ies is the timing of the survey post intervention [26]. In
a similar study comparing patient preferences for CT
colonography verses colonoscopy, van Gelder et al re-
ported that patient preference for CT colonography fell
from 71% immediately after the tests to 61% 5 weeks
later, and that drivers for preference switched from
physical discomfort to relative diagnostic accuracy
[16]. In the current study, we instructed patients to com-
plete questionnaires after all their diagnostic tests had
been completed rather than using a fixed time point
[27]. The median return time in the current study was
1 week, although this ranged widely from 0 to 47
weeks. There was some evidence that after 5 weeks
the perceived importance of a few attributes related to
scan discomfort declined over time (although no signif-
icance was found after statistical correction). The rating
of diagnostic accuracy as the priority for patients was
not influenced by the time between the tests and ques-
tionnaire response, nor was overall patient scan prefer-
ence, suggesting that our findings are robust.
Overall, it is clear therefore that the choice of imaging
investigation should be based on a discussion between the
referring clinician, radiologist and patient, considering scan
attributes including diagnostic accuracy, patient experiences
and priorities, and the exact underlying clinical question.
This study has limitations. Although the largest prospective
study of patients’ experiences of cross-sectional imaging in
Crohn’s disease to date, questionnaire response rates were
under 50% despite the large majority stating that they would
participate initially. However, this is consistent with question-
naire studies of similar design (e.g. [15, 28]). Non-responders
were significantly younger than those who completed ques-
tionnaires, which may restrict generalisability. Postcode data
were unavailable so we were unable to examine the influence
of deprivation on questionnaire completion rates or scan bur-
den/preference.
Since patients had already consented to the METRIC
trial, the cohort sampled were apparently willing to under-
go these tests in the first place. It would have been inter-
esting to question those declining participation as to
whether prior experience of either test had influenced
their decision. We did not specifically record the experi-
ence of patients who did not complete or interrupted their
imaging examination which would have been informative.
In addition, some patients did not complete the question-
naire until weeks after their scan, and their recall of scan
experiences may be imperfect. However, as noted above,
the effect of such delay on reported experiences did not
impact patient preferences. Finally, we used a variety of
questionnaires, which, although comprehensive, may not
fully capture the subtleties of patient experience.
In summary, bothMRE and US are well tolerated generally
by patients with CD, and better than colonoscopy. However,
patient burden and recovery are significantly inferior for MRE
compared to US. Whilst a majority of patients would opt to
undergo US rather than MRE, patients rate other scan attri-
butes, notably diagnostic accuracy, as more important than
discomfort.
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